Pharmadrug Ready To Become Reference In European Cannabis Market
Pharmadrug Inc (CA:BUZZ – $0.03 & US:LMLLF – $0.02) is building a leading vertically-integrated medical cannabis company with a focus on the European and Israeli markets. Reasons to own Pharmadrug stock:
1. A cannabis gateway to Europe: by 2028 the European medical cannabis market is estimated to be $123 billion, making it the largest cannabis market on the planet. Pharmadrug has one of 15 licenses in Germany and is early to the European medical cannabis game. Before long, we believe markets will begin to pay attention to Pharmadrug, as one of the only pure plays into Europe.
2. Sales Growth in Germany: Pharmadrug is currently producing revenue from its operations in Germany. Currently the company is importing product from the Netherlands, but significant upside exists through larger allocations from the Netherlands and supply agreements from Canada and Israel.
3. Valuation: at a $2 million market cap, Pharmadrug is one of the cheapest companies on our radar. Trading for less than half of its invested capital, management and insiders continue to purchase shares in the Company. As some of our sensitivity analysis will show, Pharmadrug is on the verge of generating significant revenue at healthy margins.
4. Building a Retail Dispensary Brand: We are very bullish on the Company’s recent closing on their majority acquisition of CannabiSendak in Israel. Israel is a global leader in medical cannabis with a burgeoning number of patients. Most importantly, Pharmadrug has partnered with the country’s biggest cannabis guru and it doesn’t take many patients for the cash to begin rolling in under their retail dispensary/clinic model. This retail presence will grow to Pharmadrug’s base in Europe.
We reiterate our buy recommendation for Pharmadrug with a price target of $0.21, which is 600% above today’s stock price.
Download the third quarter 2019 Pharmadrug Company Report.
|Smallcaps Recommendation: Buy||Price Target: $0.21||Latest Company Report (pdf)|
|For important disclosures, please read our disclaimer.|